Yizong Hu

Yizong Hu

Auto-generated profile, based on publicly available information

Yizong Hu

Institute for Nanobiotechnology, Johns Hopkins University, Baltimore, MD, USA.

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SLSixuan Li
Sixuan Li
YHYizong Hu
Yizong Hu
ALAndrew Li
Andrew Li
JLJinghan Lin
Jinghan Lin
KHKuangwen Hsieh
Kuangwen Hsieh
HMHai-Quan Mao
Hai-Quan Mao
Lipid nanoparticles (LNPs) are effective vehicles to deliver mRNA vaccines and therapeutics. It has been challenging to assess mRNA packaging characteristics in LNPs, including payload distribution and capacity, which are critical to understanding structure-property-function relationships for further carrier development. Here, we report a method based on the multi-laser cylindrical illumination confocal spectroscopy (CICS) technique to examine mRNA and lipid contents in LNP formulations at the single-nanoparticle level. By differentiating unencapsulated mRNAs, empty LNPs and mRNA-loaded LNPs via coincidence analysis of fluorescent tags on different LNP components, and quantitatively resolving single-mRNA fluorescence, we reveal that a commonly referenced benchmark formulation using DLin-MC3 as the ionizable lipid contains mostly 2 mRNAs per loaded LNP with a presence of 40%–80% empty LNPs depending on the assembly conditions. Systematic analysis of different formulations with control variables reveals a kinetically controlled assembly mechanism that governs the payload distribution and capacity in LNPs. These results form the foundation for a holistic understanding of the molecular assembly of mRNA LNPs.

1 June 2017 in Biomaterials
Verified
Journal Article
Closed access
ZHZhiyu He
Zhiyu He
JSJose Luis Santos
Jose Luis Santos
HTHoukuan Tian
Houkuan Tian
HHHuahua Huang
Huahua Huang
YHYizong Hu
Yizong Hu
HMHai-Quan Mao
Hai-Quan Mao

11 December 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YZYining Zhu
Yining Zhu
JMJingyao Ma
Jingyao Ma
RSRuochen Shen
Ruochen Shen
JLJinghan Lin
Jinghan Lin
SLShuyi Li
Shuyi Li
HMHai-Quan Mao
Hai-Quan Mao

4 March 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JWJacob Witten
Jacob Witten
YHYizong Hu
Yizong Hu
RLRobert Langer
Robert Langer
DADaniel G. Anderson
Daniel G. Anderson
Nanoparticle-based RNA delivery has shown great progress in recent years with the approval of two mRNA vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a liver-targeted siRNA therapy. Here, we discuss the preclinical and clinical advancement of new generations of RNA delivery therapies along multiple axes. Improvements in cargo design such as RNA circularization and data-driven untranslated region optimization can drive better mRNA expression. New materials discovery research has driven improved delivery to extrahepatic targets such as the lung and splenic immune cells, which could lead to pulmonary gene therapy and better cancer vaccines, respectively. Other organs and even specific cell types can be targeted for delivery via conjugation of small molecule ligands, antibodies, or peptides to RNA delivery nanoparticles. Moreover, the immune response to any RNA delivery nanoparticle plays a crucial role in determining efficacy. Targeting increased immunogenicity without induction of reactogenic side effects is crucial for vaccines, while minimization of immune response is important for gene therapies. New developments have addressed each of these priorities. Last, we discuss the range of RNA delivery clinical trials targeting diverse organs, cell types, and diseases and suggest some key advances that may play a role in the next wave of therapies.

1 May 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
ZHZhiyu He
Zhiyu He
YHYizong Hu
Yizong Hu
ZGZaizhi Gui
Zaizhi Gui
YZYang Zhou
Yang Zhou
TNTianqi Nie
Tianqi Nie
HMHai-Quan Mao
Hai-Quan Mao

25 January 2018 in Nanoscale
Verified
Journal Article
Closed access
PDF file
ZHZhiyu He
Zhiyu He
ZLZhijia Liu
Zhijia Liu
HTHoukuan Tian
Houkuan Tian
YHYizong Hu
Yizong Hu
LLLixin Liu
Lixin Liu
YCYongming Chen
Yongming Chen
Scalable manufacturing continues to present a major barrier for clinical translation of nanotherapeutics. Methods available for fabricating protein-encapsulating nanoparticles in a scalable fashion are scarce. Protein delivery often requires multiple functionalities to be incorporated into the same vehicle. Specifically for nanoparticle-mediated oral delivery of protein therapeutics, protection in GI tract, site-specific release, facilitating transmucosal permeation, and enhancing epithelial transport are a few desirable features to be engineered into a nanoparticle system. Here we devised a sequential flash nanocomplexation (FNC) technique for the scalable production of a core–shell structured nanoparticle system by combining materials choice and particle size and structure to fulfill these functions, therefore enhancing the delivery efficiency of insulin. This method is highly effective in controlling the size, generating core–shell structure with high encapsulation efficiency (97%) and payload capacity (67%) using insulin/L-penetratin complex nanoparticles as a core coated with hyaluronic acid (HA). Both the in vitro and in vivo models confirmed that the HA coating on these core–shell nanoparticles enhanced the permeation of nanoparticles through the intestinal mucus layer and improved trans-epithelial absorption of insulin nanoparticles; and the enhancement effect was most prominent using HA with the highest average molecular weight. The insulin-loaded nanoparticles were then encapsulated into enteric microcapsules (MCs) in an FNC process to provide additional protection against the acidic environment in the stomach while allowing rapid release of insulin nanoparticles when they reach small intestine. The optimized multifunctional MCs delivered an effective glucose reduction in a Type I diabetes rat model following a single oral administration, yielding a relative bioavailability of 11% in comparison with subcutaneous injection of free-form insulin. This FNC technique is highly effective in controlling particle size and structure to improve delivery properties and function. It can be easily extended to oral delivery for other protein therapeutics.